Pattern Bioscience develops a culture-free, single-cell microbiology platform that uses machine learning to identify causal bacterial pathogens and profile antibiotic susceptibility in hours. The company’s first tests target critically ill hospitalized patients with pneumonia and bacteremia, and its initial pneumonia test received FDA Breakthrough Device Designation in December 2021. Pattern says the technology will expand to a full menu of infectious-disease tests in the future. The company will use new funding to complete development of its rapid phenotypic test platform, run clinical validation studies, and submit the platform and the initial pneumonia test for FDA review. Pattern is led by co-founder and CEO Nick Arab and is based in Austin, Texas. The press release frames the product as a response to the global threat of antimicrobial resistance and the need for faster, targeted antibiotic treatment. Pattern Bioscience develops a next-generation clinical microbiology platform based on patented phenotypic single-cell technology to identify pathogens and determine antibiotic response without traditional culture steps. Its Digital CultureTM single-cell analysis platform uses digital cell reactors combined with machine learning to produce millions of measurements per run and assess real-time antibiotic response of individual bacterial cells within the first critical hours of illness. The company aims to accelerate development and validation of this bacterial testing technology to shorten diagnostic timelines for complex infections. Pattern is led by CEO Nick Arab and was founded in 2016. The recent financing is intended to fund continued product development and validation efforts.

Total raised

$38M

Funding rounds

2

Latest round

Series C

Latest activity

Apr 2023